Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
CARTITUDE-1 study: Are responses with cilta-cel deep and durable?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Deepu Madduri, Icahn School of Medicine at Mount Sinai, New York, US, about the CARTITUDE-1 study. We asked, Are responses with ciltacabtagene autoleucel (cilta-cel) deep and durable? Madduri discusses the preliminary data from the CARTITUDE-1 study evaluating cilta-cel in patients with relapsed/refractory multiple myeloma.
Subanalysis of KarMMA study (idecabtagene vicleucel in MM) and updated results o...
In an interview with Targeted Oncology, Jesus G. Berdeja, MD, discussed a subanalysis of the KarMMA study and updated results from CARTITUDE-1, which provide insights on the use CAR T-cell therapy in heavily pretreated patients with multiple myeloma, including the elderly and frail.